Merck partners with Pfizer, Amgen and Incyte to study promising cancer drug
This article was originally published in Scrip
Executive Summary
As it pushes forward with plans to win approval for a potentially groundbreaking new cancer therapy, Merck & Co, is collaborating with competitors Pfizer, Amgen and Incyte to study how its drug works in combination with other companies’ medicines.